36 / 46
Fig.
2
–
Association
of
plasma
AR
status with
clinical
outcome
in
castration-resistant
prostate
cancer
patients
treated with
either
docetaxel
or
AR-
E U R O P E A N
U R O L O GY
X X X
( 2 0 18
)
X X X
–
X X X
4
EURURO-8056; No.
of
Pages
5
AR normal might obtain greater
benefit from abi/enza than docetaxel
Conteducta V. Eur Urol 2018